Answers are grounded in this paper and cite their sources.
FLT3 -rearranged myeloid/lymphoid neoplasm with eosinophilia is a rare, aggressive blood cancer driven by a faulty gene fusion involving a tyrosine kinase; it affects both myeloid and lymphoid blood cells and is accompanied by high levels of eosinophils. Here, we report a POZ/BTB and AT hook containing zinc finger 1 ( PATZ1 ) ::FLT3 fusion arising from a four-way translocation, t(1;22;13;5)(q25;q12;q12;q34), found as the sole aberration in tumor cells from a 71-year-old patient presenting with marked eosinophilia, Löffler-like endocarditis, and concurrent classical Hodgkin lymphoma. The PATZ1::FLT3 fusion was confirmed by molecular analysis as an in-frame fusion retaining the tyrosine kinase domains of FLT3 . Although PATZ1::FLT3 has been previously reported, its occurrence in a patient with marked eosinophilia, Löffler-like endocarditis, and concurrent classical Hodgkin lymphoma highlights the clinical and biological complexity of FLT3 -rearranged MLN-TK. This case further expands the molecular spectrum of FLT3 -rearranged myeloid/lymphoid neoplasms with eosinophilia, and the identification of a potentially targetable FLT3 rearrangement may also have therapeutic implications for similar eosinophilic neoplasms.
No takes yet. Share an insight, caveat, or question.
Brunetti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: